Business & Finance

Biopharm company focused on nosocomial infections reports Q2 2005 results

Published in Drug Week, September 2nd, 2005

Inhibitex, Inc. (INHX) announced its financial results for the second quarter ended June 30, 2005, and provided an update to its financial guidance related to the company's 2005 fiscal year-end results.

The company also reported that, as of July 31, 2005, it had enrolled more than 1,500 patients in a phase 3 clinical trial of its lead product candidate, Veronate.

William D. Johnston, PhD, president and chief executive officer of Inhibitex, said, "Our phase 3 clinical trial for Veronate for the prevention of hospital-associated infections in premature, very low birth weight infants continues to enroll well."

At June 30, 2005, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-09-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry